NYSE:ABT - Abbott Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$69.97 -1.52 (-2.13 %)
(As of 01/23/2019 03:55 PM ET)
Previous Close$71.49
Today's Range$69.27 - $71.55
52-Week Range$55.58 - $74.92
Volume504,389 shs
Average Volume6.30 million shs
Market Capitalization$122.89 billion
P/E Ratio27.99
Dividend Yield1.79%
Beta1.24
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP00282410
Phone224-667-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$27.39 billion
Cash Flow$4.6897 per share
Book Value$17.87 per share

Profitability

Net Income$477 million

Miscellaneous

Employees99,000
Outstanding Shares1,756,330,000
Market Cap$122.89 billion
OptionableOptionable

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Friday, December 14th. Stockholders of record on Tuesday, January 15th will be paid a dividend of $0.32 per share on Friday, February 15th. This represents a $1.28 annualized dividend and a dividend yield of 1.83%. The ex-dividend date of this dividend is Monday, January 14th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.28. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) issued its quarterly earnings data on Wednesday, January, 23rd. The healthcare product maker reported $0.81 earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of $0.81. The healthcare product maker had revenue of $7.77 billion for the quarter, compared to analysts' expectations of $7.82 billion. Abbott Laboratories had a return on equity of 16.05% and a net margin of 2.91%. Abbott Laboratories's revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.74 earnings per share. View Abbott Laboratories' Earnings History.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, January 23rd 2019. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its FY19 earnings guidance on Wednesday, January, 23rd. The company provided earnings per share guidance of $3.15-3.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.20. Abbott Laboratories also updated its FY 2019 guidance to $3.15-3.25 EPS.

What price target have analysts set for ABT?

21 brokerages have issued 12 month price targets for Abbott Laboratories' shares. Their predictions range from $68.00 to $86.00. On average, they anticipate Abbott Laboratories' share price to reach $76.8474 in the next twelve months. This suggests a possible upside of 9.7% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

What is the consensus analysts' recommendation for Abbott Laboratories?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 3 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

Has Abbott Laboratories been receiving favorable news coverage?

News articles about ABT stock have trended negative this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Abbott Laboratories earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media stories about the healthcare product maker a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next few days.

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:
  • Mr. Miles D. White, Chairman & CEO (Age 64)
  • Mr. Robert B. Ford, Pres & COO (Age 45)
  • Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
  • Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 40)

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by many different of retail and institutional investors. Top institutional investors include Strs Ohio (0.06%), Atalanta Sosnoff Capital LLC (0.06%), Gateway Investment Advisers LLC (0.06%), Nisa Investment Advisors LLC (0.05%), Retirement Systems of Alabama (0.05%) and Park National Corp OH (0.03%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Pederson, Michael J Warmuth, Miles D White, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Which institutional investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Sit Investment Associates Inc., Dalton Greiner Hartman Maher & Co., Gulf International Bank UK Ltd, Gradient Investments LLC, Assenagon Asset Management S.A., Stralem & Co. Inc. and Prentiss Smith & Co. Inc.. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Jaime Contreras, Jared Watkin, Michael J Pederson, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Which institutional investors are buying Abbott Laboratories stock?

ABT stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Patten & Patten Inc. TN, Gillespie Robinson & Grimm Inc., Centre Asset Management LLC, Town & Country Bank & Trust CO dba First Bankers Trust CO, Cullinan Associates Inc., Nachman Norwood & Parrott Inc and MinichMacGregor Wealth Management LLC. View Insider Buying and Selling for Abbott Laboratories.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $70.0561.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $123.04 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is http://www.abbott.com.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.


MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  716 (Vote Outperform)
Underperform Votes:  577 (Vote Underperform)
Total Votes:  1,293
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel